- Home
- ROIV vs QRVO Comparison
ROIV vs QRVO Comparison
Compare ROIV & QRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- QRVO
- Stock Information
- Founded
- ROIV 2014
- QRVO 1957
- Country
- ROIV United Kingdom
- QRVO United States
- Employees
- ROIV N/A
- QRVO N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- QRVO Semiconductors
- Sector
- ROIV Health Care
- QRVO Technology
- Exchange
- ROIV Nasdaq
- QRVO Nasdaq
- Market Cap
- ROIV 7.8B
- QRVO 7.1B
- IPO Year
- ROIV N/A
- QRVO 1997
- Fundamental
- Price
- ROIV $11.55
- QRVO $85.28
- Analyst Decision
- ROIV Buy
- QRVO Hold
- Analyst Count
- ROIV 3
- QRVO 20
- Target Price
- ROIV $15.25
- QRVO $89.84
- AVG Volume (30 Days)
- ROIV 6.5M
- QRVO 1.6M
- Earning Date
- ROIV 08-07-2025
- QRVO 07-29-2025
- Dividend Yield
- ROIV N/A
- QRVO N/A
- EPS Growth
- ROIV N/A
- QRVO N/A
- EPS
- ROIV N/A
- QRVO 0.58
- Revenue
- ROIV $29,053,000.00
- QRVO $3,718,971,000.00
- Revenue This Year
- ROIV $3.28
- QRVO $0.65
- Revenue Next Year
- ROIV $156.84
- QRVO $5.13
- P/E Ratio
- ROIV N/A
- QRVO $148.62
- Revenue Growth
- ROIV N/A
- QRVO N/A
- 52 Week Low
- ROIV $8.73
- QRVO $49.46
- 52 Week High
- ROIV $13.06
- QRVO $125.24
- Technical
- Relative Strength Index (RSI)
- ROIV 55.27
- QRVO 48.69
- Support Level
- ROIV $11.31
- QRVO $86.19
- Resistance Level
- ROIV $11.64
- QRVO $88.94
- Average True Range (ATR)
- ROIV 0.29
- QRVO 2.08
- MACD
- ROIV 0.00
- QRVO -0.65
- Stochastic Oscillator
- ROIV 78.60
- QRVO 7.96
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About QRVO Qorvo Inc.
Qorvo represents the combined entity of RF Micro Devices and TriQuint Semiconductor, which merged in January 2015. The company specializes in radio frequency filters, power amplifiers, and front-end modules used in many of the world's most advanced smartphones. Qorvo also has a suite of products sold into a variety of nonsmartphone end markets, such as wireless base stations, cable TV and networking equipment, and infrastructure and military applications.